Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypertension (HTN): later-stage trial registry
3 of 4 indexed Hypertension (HTN) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Hypertension (HTN): 4 US clinical trials tracked, 3 recruiting.
Hypertension (HTN) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Anita Misra-Hebert, running 1 of these trials.
Enrollment posture brief
Registry condition hypertension-htn
OPEN 3 | RECR 75% | LATE 1 | EARLY 0 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Hypertension (HTN) lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypertension (HTN) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypertension (HTN) is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Study of the Progression of Chronic Cardiovascular Conditions
Prolaio
NCT07420907
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
Anita Misra-Hebert
NCT07232017
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
Sarfez Pharmaceuticals
NCT07223502
Mediterranean-DASH Intervention for Neurodegenerative Delay and High-Intensity Interval Training in Adults With Hypertension
Texas Woman's University
NCT07130539
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypertension (HTN) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypertension (HTN) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypertension (HTN) page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Hypertension (HTN) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Anita Misra-Hebert sponsors the most Hypertension (HTN) trials on record, review their full trial history before evaluating a specific study. See Anita Misra-Hebert's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypertension (HTN) condition card totals 4 registered trials; most-linked intervention Mind Hiit; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.